Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Non-Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
45 drugs · 284 active trials
27 drugs · 479 active trials
56 drugs · 2,316 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 12 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tisagenlecleucel | Phase 3 | Phase 3 | 5 | 3 | 2 | 20 | 0 | — | — | Mar 17, 2010 |
| Inotuzumab Ozogamicin | Phase 3 | Phase 3 | 5 | 3 | 3 | 10 | 0 | — | — | 2007-11 |
| Aldesleukin | Phase 3 | Phase 3 | 4 | 4 | 1 | 22 | 0 | — | — | 1995-05 |
| Vemurafenib | Phase 3 | Phase 3 | 4 | 2 | 1 | 8 | 0 | — | — | Apr 12, 2012 |
| Dabrafenib | Phase 3 | Phase 3 | 4 | 1 | 1 | 5 | 0 | — | — | Aug 17, 2015 |
| Nelarabine | Phase 3 | Phase 3 | 3 | 2 | 4 | 14 | 0 | — | — | 1997-06 |
| Ofatumumab | Phase 3 | Phase 3 | 2 | 2 | 5 | 41 | 0 | — | — | 2004-09 |
| Aspirin | Phase 3 | Phase 3 | 2 | 0 | 3 | 8 | 0 | — | — | 2007-01 |
| Chlorambucil | Phase 3 | Phase 3 | 2 | 0 | 5 | 8 | 0 | — | — | 2001-06 |
| Alectinib | Phase 3 | Phase 3 | 2 | 2 | 1 | 2 | 0 | — | — | Dec 18, 2023 |
| Alisertib | Phase 3 | Phase 3 | 1 | 0 | 1 | 11 | 0 | — | — | Jul 11, 2008 |
| Avelumab | Phase 3 | Phase 3 | 1 | 0 | 1 | 9 | 0 | — | — | Dec 16, 2016 |
| Cobimetinib | Phase 3 | Phase 3 | 1 | 1 | 1 | 3 | 0 | — | — | Nov 13, 2017 |
| Teniposide | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | Apr 15, 2013 |
| Sugemalimab | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | 2027-06 |
| Tamoxifen | Phase 3 | Phase 3 | 1 | 0 | 1 | 1 | 0 | — | — | 2024-04 |
| Alemtuzumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 38 | 0 | — | — | 2000-04 |
| Everolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 21 | 0 | — | — | 2004-04 |
| Mitoxantrone | Phase 3 | Phase 3 | 0 | 0 | 2 | 17 | 0 | — | — | 2001-04 |
| Enzastaurin | Phase 3 | Phase 3 | 0 | 0 | 2 | 8 | 0 | — | — | 2002-06 |
| Tanespimycin | Phase 3 | Phase 3 | 0 | 0 | 2 | 8 | 0 | — | — | 1999-06 |
| Perifosine | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | 2005-12 |
| Bleomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | Jan 8, 2006 |
| Idarubicin | Phase 3 | Phase 3 | 0 | 0 | 3 | 4 | 0 | — | — | 2002-08 |
| Pixantrone | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2001-12 |
| Imatinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2016-08 |
| Masitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2005-02 |
| Ibandronic Acid | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2006-02 |
| Ruxolitinib | Phase 2 | Phase 2 | 13 | 12 | 0 | 20 | 0 | — | — | 2008-03 |
| Thiotepa | Phase 2 | Phase 2 | 10 | 3 | 0 | 28 | 0 | — | — | 2003-04 |
| Nirogacestat | Phase 2 | Phase 2 | 8 | 2 | 0 | 10 | 0 | — | — | Sep 23, 2019 |
| Atezolizumab | Phase 2 | Phase 2 | 5 | 0 | 0 | 17 | 0 | — | — | Sep 15, 2015 |
| Palbociclib | Phase 2 | Phase 2 | 5 | 1 | 0 | 13 | 0 | — | — | 2004-09 |
| Cemiplimab | Phase 2 | Phase 2 | 5 | 4 | 0 | 6 | 0 | — | — | Apr 4, 2017 |
| Durvalumab | Phase 2 | Phase 2 | 4 | 3 | 0 | 19 | 0 | — | — | 2015-05 |
| Sintilimab | Phase 2 | Phase 2 | 4 | 2 | 0 | 10 | 0 | — | — | Nov 1, 2019 |
| Sunitinib | Phase 2 | Phase 2 | 4 | 2 | 0 | 9 | 0 | — | — | 2006-09 |
| Abexinostat | Phase 2 | Phase 2 | 4 | 1 | 0 | 8 | 0 | — | — | 2007-11 |
| Paclitaxel | Phase 2 | Phase 2 | 4 | 3 | 0 | 8 | 0 | — | — | May 18, 2001 |
| Binimetinib | Phase 2 | Phase 2 | 4 | 1 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 4 | 0 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Larotrectinib | Phase 2 | Phase 2 | 4 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Clofarabine | Phase 2 | Phase 2 | 3 | 3 | 0 | 22 | 0 | — | — | 2004-10 |
| Temozolomide | Phase 2 | Phase 2 | 3 | 3 | 0 | 9 | 0 | — | — | 2006-11 |
| Tislelizumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 9 | 0 | — | — | Apr 13, 2018 |
| Tretinoin | Phase 2 | Phase 2 | 3 | 2 | 0 | 8 | 0 | — | — | 2013-12 |
| Olaparib | Phase 2 | Phase 2 | 3 | 2 | 0 | 6 | 0 | — | — | Mar 14, 2016 |
| Vismodegib | Phase 2 | Phase 2 | 3 | 1 | 0 | 6 | 0 | — | — | 2010-12 |
| Brexucabtagene Autoleucel | Phase 2 | Phase 2 | 3 | 3 | 0 | 5 | 0 | — | — | Nov 9, 2015 |
| Pemetrexed | Phase 2 | Phase 2 | 3 | 1 | 0 | 5 | 0 | — | — | 2009-02 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.